Skip to content

BioMarin Pharmaceuticals BMRN Other Non-Current Assets

Other Non-Current Assets at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$18.62M+12.1%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$300K+37.6%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$20.1M-8.6%
Biogen logo
BiogenBIIB
$777.5M+39.1%
Globus Medical logo
Globus MedicalGMED
$78.96M+5.5%
Cytokinetics logo
CytokineticsCYTK
$18.47M+45.5%

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's other non-current assets?
BioMarin Pharmaceuticals (BMRN) reported other non-current assets of $276.42M in Q1 2026.
How has BioMarin Pharmaceuticals's other non-current assets changed year-over-year?
BioMarin Pharmaceuticals's other non-current assets increased by 17.3% year-over-year, from $235.65M to $276.42M.
What is the long-term trend for BioMarin Pharmaceuticals's other non-current assets?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's other non-current assets has grown at a 14.3% compound annual growth rate (CAGR), from $142.24M to $277.05M.
What does other non-current assets mean?
Miscellaneous long-term assets that are not classified in other specific categories.
How do you interpret other non-current assets?
Significant increases may warrant investigation into the nature of the underlying assets, such as long-term strategic investments or non-core holdings.
How does other non-current assets compare across companies?
Varies widely by company; usually a small percentage of total assets unless specific strategic investments are held.